Biocon's Canadian subsidiary secured Health Canada approval for Yesintek® (ustekinumab) Autoinjector Pen.

Biocon LimitedBIOCON · Filed with the exchange

This new format strengthens Biocon's immunology portfolio in Canada, providing a unique patient option for autoimmune conditions like psoriasis and Crohn's disease, boosting market access.

Read the original filing(PDF)

No comments yet. Be the first.

More from Biocon Limited

All announcements

Dividend/Bonus09-09-2026
General Updates
Investor Meet08-09-2026
Analysts/Institutional Investor Meet/Con. Call Updates
New Orders08-09-2026
Press Release
Investor Meet31-08-2026
Analysts/Institutional Investor Meet/Con. Call Updates
Updates28-08-2026
General Updates
Important25-08-2026
Updates

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.